IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY.

Valneva Austria GmbH0 个研究点目标入组 570 人开始时间: 2019年3月25日最近更新: 2020年11月23日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Valneva Austria GmbH
入组人数: 570

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Subject is aged 18 to 65 years at the day of screening (Visit 0);
•2. Subject is of good general health, including subjects with pharmacologically controlled chronic conditions;
•3. Subject has an understanding of the study and its procedures, agrees to its provisions, and gives written informed consent prior to any study-related procedures;
•4. If subject is of childbearing potential:
•a) Subject has a negative serum pregnancy test at screening (Visit 0);
•b) Subject agrees to employ adequate birth control measures for the duration of the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 550
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

排除标准

•1. Subject has a chronic illness related to Lyme borreliosis (LB), an active symptomatic LB as suspected or diagnosed by a physician, or received treatment for LB within the last 3 months prior to Visit 0;
•2. Subject received previous vaccination against LB;
•3. Subject had a tick bite within 4 weeks prior to Visit 1;
•4. Subject has a medical history of or currently has a clinically relevant disease (e.g. cardiovascular, respiratory, neurologic, psychiatric conditions) which poses a risk for participation in the study, based on investigators judgement, such as individuals with poorly controlled or unstable disease, ongoing suspected or active inflammation, or poor compliance with pharmacologic treatment. Subjects with pharmacologically controlled conditions like osteoarthritis, depression, or asthma are eligible;
•5. Subject has a medical history of or currently has a neuroinflammatory or autoimmune disease, including Guillain Barré Syndrome;
•6. Subject has a known thrombocytopenia, bleeding disorder, or received anticoagulants in the 3 weeks prior to first vaccination or until Day 57 (Visit 3), contraindicating I.M. vaccination as judged by the investigator;
•7. Subject has received an active or passive immunization within 28 days before first vaccination at Visit 1 and until Day 85; except for influenza (seasonal or pandemic) and pneumococcal vaccines which may be administered outside a 7-days interval before or after any trial vaccination;
•8. Subject has received any other non-registered medicinal product in another clinical trial within 28 days prior to VLA15 vaccination at Visit 1 (Day 1) and throughout the entire study period or has received a registered medicinal product in another clinical trial within 28 days prior to VLA15 vaccination at Visit 1 (Day 1) and up to Day 85;
•9. Subject has a known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired immunodeficiency, including infection with human immunodeficiency virus (HIV), status post organ transplantation or immuno-suppressive therapy within 30 days prior to Visit 1. Immuno-suppressive therapy is defined as administration of chronic (longer than 14 days) prednisone or equivalent greater or equal 0.05 mg/kg/day. Topical and inhaled steroids are allowed;
•10. Subject has a history of anaphylaxis or severe allergic reactions or a known hypersensitivity or allergic reactions to one of the components of the vaccine;
•11. Subject had any malignancy in the past 5 years. If treatment for cancer was successfully completed more than 5 years ago and the malignancy is considered to be cured, the subject may be enrolled;
•12. Subject had acute febrile infections within 10 days prior to first vaccination;
•13. Subject is pregnant (positive serum pregnancy test at screening), has plans to become pregnant during the course of the study or is lactating at the time of enrollment. Women of childbearing potential that are unwilling or unable to employ an adequate birth control measure for the duration of the study.
•14. Subject has donated blood or blood-derived products (e.g. plasma) within 30 days or received blood or blood-derived products (e.g. plasma) within 90 days prior to first vaccination in this study or plans to donate or use blood or blood products during the course of the study;
•15. Subject has any condition that, in the opinion of the investigator, may compromise the subject’s well-being, might interfe

研究者

发起方

Valneva Austria GmbH

相似试验

进行中（未招募）

1 期

YME BORRELIOSIS STUDY TO EVALUATE IMMUNE RESPONSE AND TO COLLECT SAFETY INFORMATION OF VLA15, WHICH IS A NEW VACCINE CANDIDATE. STUDY IN HEALTHY ADULTS AGED 18 TO 65 YEARS.Prevention against Lyme borreliosisMedDRA version: 20.0Level: PTClassification code 10025169Term: Lyme diseaseSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10025170Term: Lyme's diseaseSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10067559Term: Lyme borreliosisSystem Organ Class: 10021881 - Infections and infestations

EUCTR2018-003379-37-BEValneva Austria GmbH570

进行中（未招募）

1 期

EUCTR2018-003379-37-ATValneva Austria GmbH570

已完成

2 期

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.Lyme Borreliosis

NCT03769194Pfizer572

已完成

2 期

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study PopulationLyme Borreliosis

NCT04801420Pfizer625

已完成

1 期

Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)Pneumococcal Infections

NCT01215175Merck Sharp & Dohme LLC150